Hide metadata

dc.date.accessioned2024-02-14T07:56:59Z
dc.date.available2024-02-14T07:56:59Z
dc.date.created2023-01-16T09:33:34Z
dc.date.issued2023
dc.identifier.citationMori, Yuichi Wang, Pu Løberg, Magnus Misawa, Masashi Repici, Alessandro Spadaccini, Marco Correale, Loredana Antonelli, Giulio Yu, Honggang Gong, Dexin Ishiyama, Misaki Kudo, Shin-ei Kamba, Shunsuke Sumiyama, Kazuki Saito, Yutaka Nishino, Haruo Liu, Peixi Glissen Brown, Jeremy R. Mansour, Nabil M. Gross, Seth A. Kalager, Mette Bretthauer, Michael Rex, Douglas K. Sharma, Prateek Berzin, Tyler M. Hassan, Cesare . Impact of Artificial Intelligence on Colonoscopy Surveillance After Polyp Removal: A Pooled Analysis of Randomized Trials. Clinical Gastroenterology and Hepatology. 2022
dc.identifier.urihttp://hdl.handle.net/10852/108018
dc.description.abstractBackground and Aims Artificial intelligence (AI) tools aimed at improving polyp detection have been shown to increase the adenoma detection rate during colonoscopy. However, it is unknown how increased polyp detection rates by AI affect the burden of patient surveillance after polyp removal. Methods We conducted a pooled analysis of 9 randomized controlled trials (5 in China, 2 in Italy, 1 in Japan, and 1 in the United States) comparing colonoscopy with or without AI detection aids. The primary outcome was the proportion of patients recommended to undergo intensive surveillance (ie, 3-year interval). We analyzed intervals for AI and non-AI colonoscopies for the U.S. and European recommendations separately. We estimated proportions by calculating relative risks using the Mantel-Haenszel method. Results A total of 5796 patients (51% male, mean 53 years of age) were included; 2894 underwent AI-assisted colonoscopy and 2902 non-AI colonoscopy. When following U.S. guidelines, the proportion of patients recommended intensive surveillance increased from 8.4% (95% CI, 7.4%–9.5%) in the non-AI group to 11.3% (95% CI, 10.2%–12.6%) in the AI group (absolute difference, 2.9% [95% CI, 1.4%–4.4%]; risk ratio, 1.35 [95% CI, 1.16–1.57]). When following European guidelines, it increased from 6.1% (95% CI, 5.3%–7.0%) to 7.4% (95% CI, 6.5%–8.4%) (absolute difference, 1.3% [95% CI, 0.01%–2.6%]; risk ratio, 1.22 [95% CI, 1.01–1.47]). Conclusions The use of AI during colonoscopy increased the proportion of patients requiring intensive colonoscopy surveillance by approximately 35% in the United States and 20% in Europe (absolute increases of 2.9% and 1.3%, respectively). While this may contribute to improved cancer prevention, it significantly adds patient burden and healthcare costs.
dc.description.abstractImpact of Artificial Intelligence on Colonoscopy Surveillance After Polyp Removal: A Pooled Analysis of Randomized Trials
dc.languageEN
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleImpact of Artificial Intelligence on Colonoscopy Surveillance After Polyp Removal: A Pooled Analysis of Randomized Trials
dc.title.alternativeENEngelskEnglishImpact of Artificial Intelligence on Colonoscopy Surveillance After Polyp Removal: A Pooled Analysis of Randomized Trials
dc.typeJournal article
dc.creator.authorMori, Yuichi
dc.creator.authorWang, Pu
dc.creator.authorLøberg, Magnus
dc.creator.authorMisawa, Masashi
dc.creator.authorRepici, Alessandro
dc.creator.authorSpadaccini, Marco
dc.creator.authorCorreale, Loredana
dc.creator.authorAntonelli, Giulio
dc.creator.authorYu, Honggang
dc.creator.authorGong, Dexin
dc.creator.authorIshiyama, Misaki
dc.creator.authorKudo, Shin-ei
dc.creator.authorKamba, Shunsuke
dc.creator.authorSumiyama, Kazuki
dc.creator.authorSaito, Yutaka
dc.creator.authorNishino, Haruo
dc.creator.authorLiu, Peixi
dc.creator.authorGlissen Brown, Jeremy R.
dc.creator.authorMansour, Nabil M.
dc.creator.authorGross, Seth A.
dc.creator.authorKalager, Mette
dc.creator.authorBretthauer, Michael
dc.creator.authorRex, Douglas K.
dc.creator.authorSharma, Prateek
dc.creator.authorBerzin, Tyler M.
dc.creator.authorHassan, Cesare
cristin.unitcode185,52,11,0
cristin.unitnameAvdeling for helseledelse og helseøkonomi
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin2107392
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Clinical Gastroenterology and Hepatology&rft.volume=&rft.spage=&rft.date=2022
dc.identifier.jtitleClinical Gastroenterology and Hepatology
dc.identifier.volume21
dc.identifier.issue4
dc.identifier.startpage949
dc.identifier.endpage959
dc.identifier.pagecount0
dc.identifier.doihttps://doi.org/10.1016/j.cgh.2022.08.022
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn1542-3565
dc.type.versionPublishedVersion
dc.relation.projectEC/H2020 101026196


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International